天眼查商业履历信息显示，博济医药科技股份有限公司，成立于2002年，位于广州市，是一家以从事研 究和试验发展为主的企业。企业注册资本38198.9708万人民币，实缴资本10000万人民币。公司法定代 表人为王廷春。 通过天眼查大数据分析，博济医药科技股份有限公司共对外投资了39家企业，参与招投标项目112次， 知识产权方面有商标信息49条，专利信息47条，此外企业还拥有行政许可44个。 金融界消息 截至2025年8月11日收盘，博济医药（300404）报收于11.0元，上涨1.38%，换手率6.71%， 成交量18.84万手，成交金额2.06亿元。 资金流向方面，今日主力资金净流出1136.01万元，占比成交额5.51%。其中，超大单净流出132.40万 元、占成交额0.64%，大单净流出1003.60万元、占成交额4.87%，中单净流出流出661.63万元、占成交 额3.21%，小单净流入1797.64万元、占成交额8.73%。 博济医药最新一期业绩显示，截至2025一季报，公司营业总收入1.39亿元、同比减少17.06%，归属净利 润390.06万元，同比减少76.38%，扣非净利润169.79万元，同 ...

Group 1 - The core viewpoint is that Boji Pharmaceutical (300404) is one of the few CRO companies capable of providing integrated services for traditional Chinese medicine (TCM) research and development [1] - The company's TCM business has experienced rapid growth in recent years, with steady increases in service projects, orders, and revenue [1] - The increasing emphasis from the government on the TCM industry is expected to create new development opportunities for the sector [1]

Core Viewpoint - The company, Boji Pharmaceutical, is primarily focused on innovative drug development, with a diverse portfolio that includes chemical drugs, biological drugs, and traditional Chinese medicine [1] Group 1: Drug Development - The company has completed Phase III clinical trials and launched innovative drugs such as recombinant human albumin injection (from rice) and sildenafil hydrochloride tablets [1] - A self-developed traditional Chinese medicine new drug (Category 1.1) has completed Phase III clinical trials, while a collaborative development project in the same category is currently in Phase III [1] Group 2: Research and Technology - The company has established databases related to researchers, clinical trial institutions, and clinical trial projects to enhance its research capabilities [1] - The company is actively exploring the application of AI technology in drug development to improve efficiency and quality, with current usage in both preclinical and clinical operations [1]

Core Insights - The company, Boji Pharmaceutical, focuses on innovative drug development, with a diverse portfolio including chemical drugs, biological drugs, and traditional Chinese medicine [1] - The company has successfully completed Phase III clinical trials and launched innovative drugs such as recombinant human albumin injection and sildenafil citrate tablets [1] - The company is actively exploring the application of AI technology in drug development to enhance efficiency and quality, with ongoing use in both preclinical and clinical operations [1] Group 1 - The company has numerous projects in service, primarily centered on innovative drugs [1] - The company has completed Phase III clinical trials for several innovative drugs and has a traditional Chinese medicine new drug in Phase III clinical trials [1] - The company has established databases related to researchers, clinical trial institutions, and clinical trial projects [1] Group 2 - The company is transferring its self-developed projects to external clients after achieving certain technical results, allowing clients to continue development [1] - The company is exploring more applications of AI technology in drug development beyond current uses [1] - The company is preparing to establish a real-world database for AI models to enhance innovative drug clinical research [3]

Core Viewpoint - The company, Boji Pharmaceutical (300404.SZ), is a specialized CRO service provider focused on offering outsourced pharmaceutical research and development services, currently not engaged in any projects related to Chikungunya virus disease [1] Group 1 - The company provides pharmaceutical R&D outsourcing services and charges technical service fees [1] - There are currently no ongoing projects related to Chikungunya virus disease [1]

Group 1 - The company, Boji Pharmaceutical (300404.SZ), is a professional CRO service provider that primarily offers outsourced pharmaceutical research and development services and charges technical service fees [1] - Currently, the company does not have any projects related to Chikungunya virus disease [1]

Core Viewpoint - The company, Boji Pharmaceutical (300404.SZ), is a specialized CRO service provider primarily offering outsourced pharmaceutical research and development services and charging technical service fees. Currently, the company's overseas business accounts for a small proportion of its overall operations [1]. Group 1 - The company focuses on providing CRO services to pharmaceutical enterprises [1] - The primary revenue model involves charging technical service fees for its services [1] - The company's international business presence is limited at this stage [1]

Group 1 - The company, Boji Pharmaceutical, is a professional CRO service provider primarily offering outsourced pharmaceutical research and development services [1] - The company's current drug pipeline focuses on innovative drugs, including chemical drugs, biological drugs, and traditional Chinese medicine, covering various therapeutic areas [1] - Additionally, the company provides clinical trial and registration application services related to medical devices [1]

（文章来源：证券日报） 证券日报网讯 7月29日晚间，博济医药发布公告称，近日，公司获得国家知识产权局颁发的两项发明专 利证书，分别为"一种托匹司他的制备方法"和"一种鞣酸小檗碱口服制剂及其制备方法"。 ...

证券日报网讯博济医药7月29日在互动平台回答投资者提问时表示，公司有多个处于不同阶段的自研项 目，该类项目由公司自主立项，拥有自主知识产权，例如用于治疗慢性心力衰竭的中药1.2类品种"CRA （原料）"及"CRA片（制剂）"，目前已获得国家药品监督管理局核准签发的《药物临床试验批准通知 书》。 （文章来源：证券日报） ...